Capital-intensive drug development
Requires significant financial resources for clinical trials.
- Materiality
- high
Isofol Medical
Isofol Medical AB is a Swedish biotechnology company focused on the development of arfolitixorin, a drug candidate aimed at improving treatment outcomes for metastatic colorectal cancer. The company is engaged in clinical trials and collaborates with international partners to expand its geographic reach. Isofol's primary goal is to address unmet medical needs in oncology through innovative first-line treatment options. The company operates from its headquarters in Gothenburg, Sweden, and leverages partnerships to enhance its research and development efforts globally.
6
6.19
6.18
| % | |
|---|---|
| Drug Development | 100% Includes the development and clinical trials of arfolitixorin. |
Isofol Medical's primary customers are pharmaceutical companies and healthcare providers involved in oncology...
- Pharmaceutical Companiesprimary
Interested in licensing and commercializing arfolitixorin for oncology.
- Healthcare Providerssecondary
Use Isofol's treatments for improving cancer patient outcomes.
- Research Institutionsemerging
Collaborate on clinical trials and research studies.
Isofol Medical is headquartered in Gothenburg, Sweden, and has a significant presence in Europe...
- •Headquartered in Gothenburg, Sweden
- •Partnerships in Japan, Canada, and the United States
- •Focus on expanding presence in Europe
- •Participation in international oncology conferences
Isofol Medical's strategic priorities include advancing the clinical development of arfolitixorin and expanding its...
01
Advance clinical trials for arfolitixorinmedium-term
To establish efficacy and secure regulatory approvals.
02
Expand geographic reachlong-term
To access new markets and increase drug availability.
Isofol Medical faces significant risks associated with the development of its sole drug candidate, arfolitixorin...
Regulatory approval challenges
Potential delays or denials can impact market entry.
- Materiality
- high
Revenue recognition
high
Swedish Orphan Biovitrum
SOBI.ST · Health Care
Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company dedicated to transforming the lives of individuals with rare and debilitating diseases.
Ascelia Pharma
ACE.ST · Health Care
Ascelia Pharma is a Swedish pharmaceutical company headquartered in Malmö, with a US base in New Jersey.
Bolt Biotherapeutics, Inc.
BOLT · Pharmaceutical Preparations
BioArctic
BIOA-B.ST · Health Care
BioArctic AB is a Swedish biopharmaceutical company focused on developing innovative treatments for severe neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS.
Cantargia
CANTA.ST · Health Care
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases.
EXELIXIS, INC.
EXEL · Biological Products, (No Diagnostic Substances)
Exelixis is a U.S.-based oncology company built around cabozantinib, which it markets as CABOMETYX and COMETRIQ and uses as the core of its commercial revenue base.
: 11/08/2026